<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="191423">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00600743</url>
  </required_header>
  <id_info>
    <org_study_id>07-101</org_study_id>
    <nct_id>NCT00600743</nct_id>
  </id_info>
  <brief_title>Effect of a CCK-1R Agonist on Food Intake in Humans</brief_title>
  <acronym>GSK</acronym>
  <official_title>Effect of a CCK-1R Agonist on Food Intake in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's-Roosevelt Hospital Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Luke's-Roosevelt Hospital Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ultimate aim of this study is to test the hypothesis that the oral CCK agonist
      GSKI181771X will reduce the size of a binge meal among individuals with Bulimia Nervosa. The
      study will be conducted in phases. First, an effective dose for reducing food intake, when
      normal subjects eat normally will be attained. Next, it will be determined whether intake at
      this dose is reduced in control subjects instructed to eat to capacity. If the dose is still
      effective compared to placebo, the same dose will be tested in patients with bulimia
      nervosa.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Significant reduction in food intake by drug compared to placebo</measure>
    <time_frame>25-30 min after taking drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Significant increase in satiation after drug compared to placebo</measure>
    <time_frame>25-30 min after taking drug</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Bulimia Nervosa</condition>
  <condition>Normal Subjects Eating to Satiation</condition>
  <condition>Normal Subjects Overeating</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Normal group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with bulimia nervosa</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSKI181771X (CCK-1R agonist)</intervention_name>
    <description>Drug one trial vs placebo</description>
    <arm_group_label>1</arm_group_label>
    <other_name>GSKI181771X</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSKI181771X (CCK-1R agonist)</intervention_name>
    <description>Drug one trial vs placebo</description>
    <arm_group_label>2</arm_group_label>
    <other_name>GSKI181771X</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both controls and patients will be female, 18 to 45 years old, and within 80-120% of
             ideal body weight (Metropolitan Life Insurance, 1983). Inclusion and exclusion will
             be evaluated using the following guidelines:

        Normal Controls:

          -  No current or past psychiatric illness

          -  No history of binge eating or vomiting

          -  80-120% ideal weight

          -  Of non-childbearing potential (i.e. physiologically incapable of becoming pregnant or
             surgically sterile)

          -  If of childbearing potential, willing to use an acceptable method of birth-control
             (please see list in &quot;Exclusion&quot; section)

        Patients with Bulimia Nervosa:

          -  DSM-IV criteria for bulimia nervosa

          -  Duration of illness &gt; 1 year

          -  Purging after binges via self-induced vomiting

        (Same as controls for remaining inclusion criteria)

        Exclusion Criteria:

        Normal Controls:

          -  Significant medical illness: CBC, Chem-1, serum electrolytes (sodium, potassium,
             chloride, CO2), glucose, BUN, creatinine, Alk Phos, ALT (SGPT), AST (SGOT), LDH,
             total bilirubin, total protein, albumin, globulin, A/G ratio, calcium, phosphorus,
             uric acid, cholesterol, triglyceride

          -  ALT outside of upper limit of normal: Chem-1

          -  History of gallstones, pancreatitis or cholecystitis

          -  Current medication

          -  Hypersensitivity to benzodiazepines (contraindication in DCSI v02, 1-March-2006)

          -  Drug or alcohol abuse in last 3 mts

          -  Pregnancy

          -  Unable or unwilling to use highly effective methods of contraception for the duration
             of the study until an insignificant amount of the investigational product remains in
             the subject (i.e. at least 5 terminal phase half-lives). Examples of highly effective
             methods of contraception are:

               -  Implants of levonorgestrel, or

               -  Injectable progestogen, or

               -  Oral birth control pills for at least 3 monthly cycles prior to administration
                  of study drug + continuation for 24 hrs after last dose of study drug, or

               -  Double-barrier method (e.g. condom, diaphragm) with spermicide

        Note-Significant medical illness is any illness requiring continued care, i.e. chronic
        medication. Examples include hypertension, diabetes, and systemic lupus erythematosis.
        Subjects with seasonal allergies or occasional urinary tract infections will be included.

        Patients with Bulimia Nervosa:

          -  Same as controls
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry R. Kissileff, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's-Roosevelt Hospital Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeanine Albu, MD</last_name>
    <role>Study Director</role>
    <affiliation>St. Luke's-Roosevelt Hospital Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Luke's/Roosevelt Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nyorc.org</url>
    <description>studies</description>
  </link>
  <verification_date>March 2010</verification_date>
  <lastchanged_date>March 3, 2010</lastchanged_date>
  <firstreceived_date>January 14, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Harry R. Kissileff</name_title>
    <organization>St. Luke's/Roosevelt Hospital</organization>
  </responsible_party>
  <keyword>Eating</keyword>
  <keyword>Food Intake</keyword>
  <keyword>Appetite</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Bulimia Nervosa</mesh_term>
    <mesh_term>Hyperphagia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
